Growing Radiopharmaceutical Market IBA's leadership in particle accelerator technology and its recent contracts with pharmaceutical companies like Telix Pharmaceuticals highlight significant demand in the radiopharmaceutical production sector, presenting substantial sales opportunities for advanced cyclotron systems and related solutions.

Expanding Global Presence Recent installations of proton therapy systems in India and the United States demonstrate IBA's successful international expansion, opening avenues to target rapidly growing healthcare markets emphasizing advanced cancer treatments with tailored sales strategies.

Strategic Industry Partnerships Collaborations with Jabil and other industrial players for X-ray and sterilization solutions suggest potential cross-selling opportunities in industrial sterilization and irradiation markets, especially as industries seek to enhance safety and compliance standards.

Innovation in Oncology The development of next-generation therapies like the CD47 blocking antibody and the production of actinium-225 for targeted cancer treatments position IBA at the forefront of oncology innovation, providing sales prospects in cutting-edge medical research and personalized medicine markets.

Strong Financial Backing With revenue between 1B and 10B and recent over-subscribed funding rounds, IBA has robust financial resources, enabling them to expand product lines and invest in new market segments, offering opportunities for strategic partnerships and enterprise-level sales initiatives.